Development stage, private biotech co. focused on personalized IPSC (autologous) cell therapies to address unmet medical needs, starting with Parkinson's (PD)
San Diego, CA
Joined July 2019
- Tweets159
- Following59
- Followers382
- Likes25
Thank you to Society for Neuroscience for inviting Aspen's Genevieve Beauvais, PhD, to present, "Dopamine and Non-Dopamine Pathways," today at the annual 2023 Society for Neuroscience meeting poster session. We are looking forward to the rest of this week's presentations!
#iPSCs
In 2022, Aspen Neuroscience’s VP of Process & Analytical Development, Thorsten Gorba, PhD, delivered an in-depth presentation at the annual iPSC-derived Cell Therapy Summit.
Our approach to the treatment of Parkinson’s Disease incorporates the Aspen-derived NeuriTest™, a bioinformatics tool designed to implement quality control for the manufacture of autologous dopamine neurons.
Today NeuriTest™ is the final quality control/product “checkpoint” for manufacturing autologous cell replacement therapy for people with Parkinson’s Disease. Tomorrow it may be leveraged for future autologous cell types and applications.
#iPSC #autologous #celltherapy #PD
Today marks an important milestone: we are excited to announce that FDA has granted Fast Track Designation for ANPD001 for the treatment of Parkinson’s disease (PD) to improve motor function.
The purpose of Fast Track Designation is to get important new drugs to patients earlier. FDA grants Fast Track Designation (FTD) to facilitate development, and to expedite the review of medicines to treat serious conditions and fill an unmet medical need.
"People with Parkinson’s disease have a significant unmet medical need and have been waiting for many years for more advanced treatment options,” said our CEO Damien McDevitt, PhD. This is a truly exciting time for our team! bit.ly/402FFh3 #iPSC #autologous #celltherapy
We are excited to be presenting at the annual Cell & Gene Meeting on the Mesa this week!
aspenneuroscience.com/aspen-…
#CGMesa23 #iPSC #autologous #celltherapy
Our Chief Scientific Officer, Xiaokui Zhang, PhD, will be presenting at Cell & Gene Meeting on the Mesa's Science Slam: Autologous iPSC-Derived Cell Therapies – Promise, Progress, and Challenges on Tuesday, October 10, 2023 at 11:15 a.m.
aspenneuroscience.com/aspen-…
#CGMesa23 #iPSC
Our Chief Technology officer, Kim Raineri, will present an Aspen Neuroscience Company Presentation at Cell & Gene Meeting on the Mesa on Tuesday, October 10, 2023 at 11:30 a.m.
aspenneuroscience.com/aspen-…
#CGMesa23 #iPSC #autologous #celltherapy
Today we announced a new collaboration with Rune Labs, a software and data analytics company for precision neurology, & Emerald Innovations, a pioneer in the creation of "invisible" off-body sensors for measuring health analytics.
We are advancing the collection of objective measures of motor function via active monitoring, working with Rune Labs’ clinical development platform, StriveStudy, and passive in-home monitoring, working with Emerald Innovations' contactless biosensors.
The use of DHT empowers trial investigators to include objective, long-term (pre-treatment) motor and sleep symptom capture, to provide data on each patient’s rate of disease progression.
For more information click the link below:
bit.ly/47Z8y1x
We plan to initiate our Phase 1/2a soon, studying ANPD001 in people with moderate to severe Parkinson’s Disease.
There are many people and organizations who have been on this journey with Aspen, & we are grateful to you all for your support and guidance in making autologous cell therapy closer to a reality for patients who are waiting. More details in the link below! bit.ly/3QrFSYB